EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PTC Therapeutics's enterprise value is €3,068.1 Mil.
PTC Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-306.5 Mil. Therefore, PTC Therapeutics's EV-to-EBITDA for today is -10.01.
The historical rank and industry rank for PTC Therapeutics's EV-to-EBITDA or its related term are showing as below:
FRA:BH3'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -106.67 Med: -9.61 Max: 3.74
Current: -9.9
During the past 13 years, the highest EV-to-EBITDA of PTC Therapeutics was 3.74. The lowest was -106.67. And the median was -9.61.
FRA:BH3's EV-to-EBITDA is ranked worse than 100% of 474
companies
in the Biotechnology industry
Industry Median: 9.165
vs FRA:BH3: -9.90
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-25), PTC Therapeutics's stock price is €23.40.
PTC Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-7.749. Therefore, PTC Therapeutics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
PTC Therapeutics EV-to-EBITDA Historical Data
The historical data trend for PTC Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of PTC Therapeutics's EV-to-EBITDA
For the Biotechnology subindustry, PTC Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PTC Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PTC Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where PTC Therapeutics's EV-to-EBITDA falls into.
PTC Therapeutics EV-to-EBITDA Calculation
PTC Therapeutics's EV-to-EBITDA for today is calculated as:
PTC Therapeutics's current Enterprise Value is €3,068.1 Mil.
PTC Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-306.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
PTC Therapeutics's PE Ratio for today is calculated as:
PTC Therapeutics's share price for today is €23.40.
PTC Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-7.749.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of PTC Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:BH3 has been successfully added to your 